Anti-fibrotic effects of interferons. Mechanisms and therapeutic prospects;Effets anti-fibrosants des interferons: Mecanismes d'action et perspectives therapeutiques

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 6-7, 1997, Pages 466-471

  Pilette, Christophe ^a   Fort, Joël ^a   Rifflet, Hervé ^a   Calés, Paul ^a,b  

^a Universite d'Angers   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Alpha interferon; Extra cellular matrix; Gamma interferon; Hepatic stellate cell; Liver fibrosis

Indexed keywords

ALPHA INTERFERON; COLLAGEN; GAMMA INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON;

ARTICLE; CELL GROWTH; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; LIVER CELL; LIVER FIBROSIS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; STELLATE CELL; ANIMAL; FIBROSIS; LIVER CIRRHOSIS; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; FIBROSIS; HUMANS; INTERFERONS; LIVER CIRRHOSIS;

EID: 0030634907     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mavier P, Rosenbaum J. La fibrose hépatique. Concepts actuels. Gastroenterol Clin Biol 1994;18:547-9.
2. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;24:1828-34.
3. Desmoulière A, Tuchweber B, Gabbiani G. Role of the myofibroblast differentiation during liver fibrosis. J Hepatol 1995;22 (Suppl 2):61-4.
4. Ucar R, Sanwo M, Ucar K, Beall G. Interferons: their role in clinical practice. Ann Allergy Asthma Immunol 1995;75:377-86.
5. Czaja J, Weiner F, Eghbali M. Differential effects of γ interferon on collagen and fibronectin gene expression. J Biol Chem 1987;262:13348-51.
6. Goldring M, Sandell L, Stephenson M. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J Biol Chem 1986;261:9049-56.
7. Reginato A, Sanz-Rodriguez C, Diaz A. Transcriptional modulation of cartilage-specific collagen gene expession by IFN γ and tumor necrosis factor α in culture human chondrocytes. Biochem J 1993;294:761-9.
8. Kähäri V, Chen Y, Wan Su M, Ramirez F, Uitto J. Tumor necrosis factor-α and interferon-γ suppress the activation of human type I colllagen gene expression by transforming growth factor-β1. J Clin Invest 1990;86:1489-95.
9. Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 1995;104:282-6.
10. Granstein R, Murphy G, Margolis R. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987;79:1254-8.
11. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23: 654-8.
12. Pittet B, Rubbia-Brandt L, Desmoulière A. Effect of γ interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg 1994;93:1224-35.
13. Rockey DC, Maher J, Jarnagin W, Gabbiani G, Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon γ. Hepatology 1992;16:776-84.
14. Mallat A, Préaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-10.
15. Czaja J, Weiner F, Takahashi S, Giambrone MA, Van Der Meide PH, Schellekens H, et al. Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1989;10:795-800.
16. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mansini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189-99.
17. Shi Z, Stewart TA, Rockey DC. Liver injury and fibrosis in interferon γ gene knockout mice (abstract). Hepatology 1995;22 (4Pt2):276A.
18. Elias I, Alpini G, Gubba S. Antiproliferative effects of γ interferon in carbon tetrachloride (CC14)-induced cirrhosis (abstract). Hepatology 1995;22 (4Pt2):277A.
19. Muriel P, Bolanos J, Barral JM, Torres G. Effect of alpha-interferon on erythrocyte and hepatocyte plasma membranes derived from cirrhotic rats. Pharmacology 1994;48:63-8.
20. Muriel P. Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in rats. J Hepatol 1996;24:614-21.
21. Fort J, Pilette C, Oberti F, Veal N, Gallois Y, Douay O, et al. Effets de l'interféron α-2a sur la fibrose hépatique et l'hypertension portale chez le rat (résumé). Gastroenterol Clin Biol 1996;20:812.
22. Israël B, Blouin R, McIntyre W, Shedlofsky S. Effects of interferon-α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993;36:229-35.
23. 2b. Biochem Pharmacol 1995;50:515-20.
24. 2b increases fibrolysis in fibrotic livers from bile duct ligated rats: possible participation of the plasminogen activator. Pharmacology 1995;51:341-6.
25. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomized trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17:390-6.
26. Hiramatsu N, Hayashi N, Kasahara A. Improvement of liver fibrosis in chronic hepatitis C patients with natural interferon α. J Hepatol 1995;22:135-42.
27. Guéchot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol 1995;22:22-6.
28. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991;11:30-8.
29. Tran Van Nhieu J, Deugnier Y, Métreau JM, Lemonnier C, Dhumeaux D, Zafrani ES. Histological response to interferon-α (IFNα) therapy in chronic hepatitis C: improvement of necrosis and fibrosis (abstract). J Hepatol 1993;18 (suppl 1):S181.
30. Kasahara A, Hayashi N, Hiramatzu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.
31. Trinchet JC. Clinical use of serum markers of fibrosis in chronic hepatitis. J Hepatol 1995;22 (Suppl 2):89-95.
32. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and a in chronic liver disease. Effects of Interferon α therapy. N Engl J Med 1991;324:933-40.
33. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, et al. α-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18:112-8.
34. Pateron D, Hartmann DJ, Berrebi W, Trinchet JC, Jouanolle H, Callard P, et al. Signification du dosage sérique du peptide N-terminal du procollagène de type III au cours des hépatites chroniques à virus C. Gastroenterol Clin Biol 1994;18:257-61.
35. Yamada M, Fukuda Y, Koyama Y, Urano F, Katano Y, Hayakawa T, et al. Serum hyaluronic acid reflects the effect of Interferon treatment on hepatic fibrosis (abstract). J Hepatol 1995;23 (Suppl 1):99.
36. Ishibashi K, Kashiwagi T, Nagasawa M, Toyama T, Tanaka Y, Ito A, et al. Long-term effects of interferon on serum fibrogenesis markers in patients with chronic hepatitis type C. Comparison between responders and nonresponders (abstract). Gastroenterology 1996;110:A1218.
37. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with Interferon alpha. Hepatology 1995;22:426-31.
38. Manabe N, Chevallier M, Chossegros P. Interferon α-2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
39. Mathurin P, Thévenot T, Sobewski R, Moussali J, Charlotte F, Opolon P, et al. Six mois d'interféron (IFN) ralentit la progression de la fibrose et de l'activité histologique chez les sujets avec hépatite chronique active C ne normalisant pas leur ALAT à 3 mois (NR-3M) (résumé). Gastroenterol Clin Biol 1996;20:822.
40. Guido M, Rugge M, Chemello L, Leandro G, Fattovich G, Guistina G, et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 1996;24:301-7.